What Is Bremelanotide? Everything You Should Know Before Starting

Bremelanotide at a glance:

• Drug class: Melanocortin receptor agonist
• Manufacturer: Palatin Technologies / AMAG Pharmaceuticals
• FDA approved: 2019
• Route: subcutaneous injection autoinjector
• Typical frequency: as needed before sexual activity
• Half-life: approximately 2.7 hours
• Cash price (US): $300-$1,000/month

Bremelanotide has become one of the more talked-about names in the melanocortin receptor agonist space. The clinical reality is more nuanced than the headlines suggest, and most of what matters fits in a few sentences. Bremelanotide is the FDA-approved name for PT-141.

What is Bremelanotide?

Bremelanotide is the FDA-approved name for PT-141. It activates melanocortin receptors in the CNS to improve sexual arousal independently of vascular mechanisms.

Bremelanotide is manufactured by Palatin Technologies / AMAG Pharmaceuticals. Bremelanotide was approved by the FDA in 2019. Its approved indications include hypoactive sexual desire disorder (HSDD) in premenopausal women. Off-label use happens in clinical practice but is the prescriber's responsibility.

The drug class melanocortin receptor agonist works by targeting specific receptor pathways. Let's walk through what that means in practice.

How Bremelanotide Works in the Body

Bremelanotide is the FDA-approved name for PT-141. It activates melanocortin receptors in the CNS to improve sexual arousal independently of vascular mechanisms. The receptor target — compound-specific — drives the downstream effects users care about: statistically significant improvement in hsdd desire and distress measures vs placebo.

The pharmacokinetics matter for daily use. Bremelanotide has a half-life of approximately 2.7 hours, which determines how often it is dosed. The standard route of administration is subcutaneous injection autoinjector, and the typical schedule is as needed before sexual activity.

For more detail on the underlying biology, see our breakdown of how Bremelanotide works.

Who Uses Bremelanotide?

Bremelanotide is most relevant for people whose situation maps to its approved indications: hypoactive sexual desire disorder (HSDD) in premenopausal women.

People who should avoid Bremelanotide include those with the following:

• allergy to the active ingredient or any excipient
• pregnancy or breastfeeding (per label)
• conditions specifically called out in the prescribing information

Common and Serious Side Effects

The most commonly reported side effects of Bremelanotide include:

• nausea
• flushing
• headache
• injection-site reactions

Serious risks — uncommon but worth knowing — include:

• transient blood pressure elevation
• hyperpigmentation

We have a more detailed breakdown in our Bremelanotide side-effects guide.

Bremelanotide vs Alternatives

Flibanserin (Addyi) is the other FDA-approved HSDD medication. Behavioral and hormonal therapies are also options. If you are weighing Bremelanotide against another option, our comparison pages include Bremelanotide Side Effects: 7 Things to Watch For (and How to Manage Them), Bremelanotide Results: What the Real Numbers Show in 2026, Why Bremelanotide Costs So Much (and 5 Ways to Pay Less).

Bottom Line

Bremelanotide fits into a broader landscape of melanocortin receptor agonist options. The right choice for any individual depends on insurance, side-effect tolerance, dosing preference, and prescriber familiarity — usually more than on the molecule itself. Multiple randomized controlled trials support its efficacy. If you are considering Bremelanotide, talk to a licensed clinician first — particularly if you take other medications.

Frequently Asked Questions

Related Reading

• Bremelanotide Side Effects: 7 Things to Watch For (and How to Manage Them)
• Bremelanotide Results: What the Real Numbers Show in 2026
• Why Bremelanotide Costs So Much (and 5 Ways to Pay Less)
• Bremelanotide Cycle and Protocol: What Researchers Actually Use
• hCG: The Complete 2026 Guide (Mechanism, Dosing, Cost)
• What Is Oxytocin? Everything You Should Know Before Starting

Sources

• Skorupskaite K et al. Kisspeptin and Reproduction in Humans. Hum Reprod Update 2014;20:485.
• Kingsberg SA et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder. Obstet Gynecol 2019;134:899.

This page is informational only and is not medical advice. Consult a licensed clinician before starting, stopping, or changing any medication.